A carregar...

New Studies Reveal Potential Mechanisms of Resistance to CDK4/6 Inhibitors in HR+/HER2– Breast Cancer

Research focused on barriers to the real‐world use of CDK4/6 inhibitor therapy in patients with HR+/HER2– breast cancer reveals potential mechanisms and biomarkers of drug resistance.

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncologist
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley & Sons, Inc. 2021
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8262301/
https://ncbi.nlm.nih.gov/pubmed/34181796
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/onco.13875
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!